(SMRI) Bushido Capital US Equity - Ratings and Ratios
Exchange: NASDAQ • Country: USA • Currency: USD • Type: Etf • • Large Value
SMRI: Stocks, Equities, Securities, Investments
The fund is an actively managed exchange-traded fund ('ETF') that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of the fund's net assets (plus the amount of any borrowings for investment purposes) in U.S. listed common stock.
Additional Sources for SMRI ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SMRI ETF Overview
| Market Cap in USD | 393m |
| Category | Large Value |
| TER | 0.71% |
| IPO / Inception | 2023-09-13 |
SMRI ETF Ratings
| Growth 5y | 76.8% |
| Fundamental | - |
| Dividend | 51.9% |
| Rel. Strength Industry | 44.5 |
| Analysts | - |
| Fair Price Momentum | 32.59 USD |
| Fair Price DCF | - |
SMRI Dividends
| Dividend Yield 12m | 0.94% |
| Yield on Cost 5y | 1.23% |
| Annual Growth 5y | 60.36% |
| Payout Consistency | 100.0% |
SMRI Growth Ratios
| Growth Correlation 3m | 25.8% |
| Growth Correlation 12m | 89% |
| Growth Correlation 5y | 95.1% |
| CAGR 5y | 22.17% |
| CAGR/Mean DD 5y | 10.29 |
| Sharpe Ratio 12m | 1.57 |
| Alpha | 4.28 |
| Beta | 0.80 |
| Volatility | 13.24% |
| Current Volume | 14.9k |
| Average Volume 20d | 10k |
What is the price of SMRI stocks?
As of January 24, 2025, the stock is trading at USD 32.69 with a total of 14,897 shares traded.
Over the past week, the price has changed by +0.69%, over one month by +4.27%, over three months by +7.76% and over the past year by +26.09%.
As of January 24, 2025, the stock is trading at USD 32.69 with a total of 14,897 shares traded.
Over the past week, the price has changed by +0.69%, over one month by +4.27%, over three months by +7.76% and over the past year by +26.09%.
Is Bushido Capital US Equity a good stock to buy?
Yes. Based on ValueRay Analyses, Bushido Capital US Equity (NASDAQ:SMRI) is currently (January 2025) a good stock to buy. It has a ValueRay Growth Rating of 76.84 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SMRI as of January 2025 is 32.59. This means that SMRI is currently overvalued and has a potential downside of -0.31%.
Yes. Based on ValueRay Analyses, Bushido Capital US Equity (NASDAQ:SMRI) is currently (January 2025) a good stock to buy. It has a ValueRay Growth Rating of 76.84 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SMRI as of January 2025 is 32.59. This means that SMRI is currently overvalued and has a potential downside of -0.31%.
Is SMRI a buy, sell or hold?
Bushido Capital US Equity has no consensus analysts rating.
Bushido Capital US Equity has no consensus analysts rating.
What are the forecast for SMRI stock price target?
According to ValueRays Forecast Model, SMRI Bushido Capital US Equity will be worth about 36 in January 2026. The stock is currently trading at 32.69. This means that the stock has a potential upside of +10.13%.
According to ValueRays Forecast Model, SMRI Bushido Capital US Equity will be worth about 36 in January 2026. The stock is currently trading at 32.69. This means that the stock has a potential upside of +10.13%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 36 | 10.1% |